Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules
Authors
Keywords
-
Journal
CANCER
Volume 121, Issue 4, Pages 490-497
Publisher
Wiley
Online
2014-10-30
DOI
10.1002/cncr.29053
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia
- (2014) Massimo Breccia et al. CANCER LETTERS
- Immunology and Immunotherapy of Chronic Myeloid Leukemia
- (2014) Mette Ilander et al. Current Hematologic Malignancy Reports
- Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications
- (2013) Tomas Pavlik et al. AMERICAN JOURNAL OF HEMATOLOGY
- Surrogate Measures and Consistent Surrogates
- (2013) Tyler J. VanderWeele BIOMETRICS
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
- (2013) T. P. Hughes et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
- (2013) Michael W. Deininger et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting survival pathways in chronic myeloid leukaemia stem cells
- (2013) A Sinclair et al. BRITISH JOURNAL OF PHARMACOLOGY
- Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?
- (2013) F.-X. Mahon et al. CLINICAL CANCER RESEARCH
- Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
- (2013) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
- (2013) Philippe Rousselot et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Monitoring of Chronic Myeloid Leukemia
- (2013) ChaoJie Zhen et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Surrogate end points for long-term outcomes in chronic myeloid leukemia
- (2013) Frank Akwaa et al. LEUKEMIA & LYMPHOMA
- Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes Evidence
- (2013) Ciani Oriana et al. VALUE IN HEALTH
- Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet
- (2012) J. Guilhot et al. BLOOD
- A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
- (2012) J. P. Radich et al. BLOOD
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- Standardized definitions of molecular response in chronic myeloid leukemia
- (2012) N C P Cross et al. LEUKEMIA
- Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia
- (2012) Juan Luis Steegmann et al. LEUKEMIA & LYMPHOMA
- Biomarkers and surrogate endpoints in clinical trials
- (2012) Thomas R. Fleming et al. STATISTICS IN MEDICINE
- Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy
- (2011) Tomáš Pavlík et al. BMC Medical Research Methodology
- Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia
- (2011) Jerald P. Radich CANCER
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia
- (2011) M Pfirrmann et al. LEUKEMIA
- A proportional hazards regression model for the subdistribution with right-censored and left-truncated competing risks data
- (2011) Xu Zhang et al. STATISTICS IN MEDICINE
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
- (2010) T. P. Hughes et al. BLOOD
- Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA
- (2010) H. E. White et al. BLOOD
- Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia
- (2010) Aref Al-Kali et al. CANCER
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Biomarkers and surrogate end points—the challenge of statistical validation
- (2010) Marc Buyse et al. Nature Reviews Clinical Oncology
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started